The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The price of Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) closed at $425.6 in the last session, down -1.85% from day before closing price of $433.61. In other words, the price has decreased by -$1.85 from its previous closing price. On the day, 1.14 million shares were traded. VRTX stock price reached its highest trading level at $434.0 during the session, while it also had its lowest trading level at $423.455.
Ratios:
We take a closer look at VRTX’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 17.15 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 32.36. For the most recent quarter (mrq), Quick Ratio is recorded 2.00 and its Current Ratio is at 2.36. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In the most recent recommendation for this company, Scotiabank on November 13, 2025, initiated with a Sector Outperform rating and assigned the stock a target price of $495. On September 25, 2025, Leerink Partners Upgraded its rating to Outperform which previously was Market Perform but kept the price unchanged to $456.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 20 ’25 when CARNEY LLOYD bought 800 shares for $426.36 per share.
Atkinson Edward Morrow III sold 2,500 shares of VRTX for $1,086,450 on Nov 17 ’25. The EVP, Chief Technical Ops. Off. now owns 16,852 shares after completing the transaction at $434.58 per share. On Nov 14 ’25, another insider, LEIDEN JEFFREY M, who serves as the Executive Chairman of the company, sold 53,604 shares for $440.72 each. As a result, the insider received 23,624,306 and left with 24,026 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRTX now has a Market Capitalization of 109119864832 and an Enterprise Value of 103530536960. As of this moment, Vertex’s Price-to-Earnings (P/E) ratio for their current fiscal year is 30.00, and their Forward P/E ratio for the next fiscal year is 20.98. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.20 while its Price-to-Book (P/B) ratio in mrq is 6.24. Its current Enterprise Value per Revenue stands at 8.831 whereas that against EBITDA is 21.973.
Stock Price History:
The Beta on a monthly basis for VRTX is 0.32, which has changed by -0.06864786 over the last 52 weeks, in comparison to a change of 0.12607694 over the same period for the S&P500. Over the past 52 weeks, VRTX has reached a high of $519.68, while it has fallen to a 52-week low of $362.50. The 50-Day Moving Average of the stock is 2.44%, while the 200-Day Moving Average is calculated to be -3.96%.
Shares Statistics:
According to the various share statistics, VRTX traded on average about 1.48M shares per day over the past 3-months and 1386750 shares per day over the past 10 days. A total of 253.95M shares are outstanding, with a floating share count of 253.06M. Insiders hold about 0.26% of the company’s shares, while institutions hold 94.65% stake in the company. Shares short for VRTX as of 1763078400 were 4006159 with a Short Ratio of 2.70, compared to 1760486400 on 3555766. Therefore, it implies a Short% of Shares Outstanding of 4006159 and a Short% of Float of 1.78.
Earnings Estimates
Its stock is currently analyzed by 23.0 different market analysts. The consensus estimate for the next quarter is $4.89, with high estimates of $5.48 and low estimates of $4.29.
Analysts are recommending an EPS of between $19.15 and $17.2 for the fiscal current year, implying an average EPS of $18.45. EPS for the following year is $20.18, with 25.0 analysts recommending between $23.75 and $18.15.
Revenue Estimates
According to 27 analysts,. The current quarter’s revenue is expected to be $3.18B. It ranges from a high estimate of $3.35B to a low estimate of $3.1B. As of. The current estimate, Vertex Pharmaceuticals, Inc’s year-ago sales were $2.91BFor the next quarter, 27 analysts are estimating revenue of $3.14B. There is a high estimate of $3.27B for the next quarter, whereas the lowest estimate is $2.99B.
A total of 29 analysts have provided revenue estimates for VRTX’s current fiscal year. The highest revenue estimate was $12.22B, while the lowest revenue estimate was $11.9B, resulting in an average revenue estimate of $11.99B. In the same quarter a year ago, actual revenue was $11.02BBased on 28 analysts’ estimates, the company’s revenue will be $13.05B in the next fiscal year. The high estimate is $14.13B and the low estimate is $12.05B.
